CD19-directed CAR T-cell therapy, CD22 CAR T, Large B-cell lymphoma, Matthew J. Frank, NCT04088890
High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen receptor (CAR) T-cell therapy aft..